Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs.

ABSTRACT: Leishmaniasis is a serious medical issue in many countries around the World, but it remains largely neglected in terms of research investment for developing new control and treatment measures. No vaccines exist for human use, and the chemotherapeutic agents currently used are scanty. Furthermore, for some drugs, resistance and treatment failure are increasing to alarming levels. The aim of this work was to identify genomic and trancriptomic alterations associated with experimental resistance against the common drugs used against VL: trivalent antimony (Sb^III, S line), amphotericin B (AmB, A line), miltefosine (MIL, M line) and paromomycin (PMM, P line). A total of 1006 differentially expressed transcripts were identified in the S line, 379 in the A line, 146 in the M line, and 1

SUBMITTER: Rastrojo A 

PROVIDER: S-EPMC6039315 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature